Open AccessTherapeutic status of hydroxychloroquine in COVID-19: A review
Author(s) -
Kirandeep Kaur,
Sandeep Kaushal,
Ishita Gupta Kaushal
Publication year - 2020
Publication title -
journal of anaesthesiology-clinical pharmacology/journal of anaesthesiology clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.466
H-Index - 32
eISSN - 2231-2730
pISSN - 0970-9185
DOI - 10.4103/joacp.joacp_313_20
Subject(s) - hydroxychloroquine , medicine , covid-19 , pandemic , intensive care medicine , rheumatoid arthritis , coronavirus , adverse effect , chloroquine , drug , clinical trial , hypoglycemia , disease , pharmacology , malaria , virology , immunology , infectious disease (medical specialty) , outbreak , insulin
Hydroxychloroquine (HCQ), a 4-aminoquinoline, is used worldwide mainly for its role in management of malaria and rheumatoid arthritis. In the present pandemic of coronavirus disease (COVID)-2019, the drug is being repurposed, based on its in vitro evidence of efficacy against coronavirus. There has been a lot of information, for and against the drug, and this review is an effort to bring forth the evidence and current understanding regarding role of HCQ in COVID-19. Clinical studies, case reports, and in vitro studies have generated conflicting results. There are concerns for use of HCQ because of the variable results and the known adverse effects like QT prolongation and hypoglycemia. In the current scenario, recommendations from Indian Council of Medical Research for use of HCQ in the prophylaxis of COVID-19 are being followed.